VTCN1 (B7-H4) is an inhibitory B7 family member overexpressed in ovarian, breast, endometrial, and other solid tumors. B7-H4 is an emerging immunotherapy and CAR-T target.
| Catalog No. | Product Name | Conjugate | Size | Price (In USD) |
|---|---|---|---|---|
| GM-Tg-hg-IP0154-Ab-3-PE | Anti-Human B7-H4/B7-H4/VTCN1 monoclonal antibody(mAb)(PE) | PE | 25T | |
| GM-Tg-hg-IP0154-Ab-3-PE | Anti-Human B7-H4/B7-H4/VTCN1 monoclonal antibody(mAb)(PE) | PE | 100T | |
| GM-Tg-hg-IP0154-Ab-3-PE | Anti-Human B7-H4/B7-H4/VTCN1 monoclonal antibody(mAb)(PE) | PE | 500T | |
| GM-Tg-hg-IP0154-Ab-3-FITC | Anti-Human B7-H4/B7-H4/VTCN1 monoclonal antibody(mAb)(FITC) | FITC | 25T | |
| GM-Tg-hg-IP0154-Ab-3-FITC | Anti-Human B7-H4/B7-H4/VTCN1 monoclonal antibody(mAb)(FITC) | FITC | 100T | |
| GM-Tg-hg-IP0154-Ab-3-FITC | Anti-Human B7-H4/B7-H4/VTCN1 monoclonal antibody(mAb)(FITC) | FITC | 500T | |
| GM-Tg-hg-IP0154-Ab-3-APC | Anti-Human B7-H4/B7-H4/VTCN1 monoclonal antibody(mAb)(APC) | APC | 25T | |
| GM-Tg-hg-IP0154-Ab-3-APC | Anti-Human B7-H4/B7-H4/VTCN1 monoclonal antibody(mAb)(APC) | APC | 100T | |
| GM-Tg-hg-IP0154-Ab-3-APC | Anti-Human B7-H4/B7-H4/VTCN1 monoclonal antibody(mAb)(APC) | APC | 500T | |
| GM-Tg-hg-IP0154-Ab-3-Biotin | Anti-Human B7-H4/B7-H4/VTCN1 monoclonal antibody(mAb)(Biotin) | Biotin | 25T, 100T, 500T |
| Target | B7-H4 (specific biomarker for human broad solid tumor / TAM) |
|---|---|
| Species | Humanized |
| Expression platform | Mammalian cell |
| Isotypes | Human IgG |
| Tag | hFc |
| Conjugate | PE / FITC / APC / Biotin |
| Size | 25T / 100T / 500T |
| Purity | >=95% (SDS-PAGE) |
| Bioactivity validation | B7-H4 binding, FACS in B7-H4 level test |
| Application | FACS and other Immunoassay for B7-H4 test |
| Products description | Anti-Human B7-H4/B7-H4/VTCN1 monoclonal antibody(mAb)(PE/FITC/APC/Biotin) is a recombinant monoclonal antibody. It specifically recognizes B7-H4 (B7 homolog 4 (VTCN1), a co-inhibitory molecule over-expressed in tumors). B7-H4 is a broad solid tumor / TAM marker. This antibody is validated by FACS for solid-tumor immune-checkpoint target assessment. It is recommended for multi-color flow cytometry panels to validate B7-H4 expression for immune-checkpoint CAR-T screening in CAR-T cell therapy manufacturing, QC and functional assessment. |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |